Search

Your search keyword '"Cordts, Isabell"' showing total 194 results

Search Constraints

Start Over You searched for: Author "Cordts, Isabell" Remove constraint Author: "Cordts, Isabell"
194 results on '"Cordts, Isabell"'

Search Results

3. Multiomic ALS signatures highlight subclusters and sex differences suggesting the MAPK pathway as therapeutic target

4. Economic evaluation of Motor Neuron Diseases: a nationwide cross-sectional analysis in Germany

5. Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study

7. A Solve-RD ClinVar-based reanalysis of 1522 index cases from ERN-ITHACA reveals common pitfalls and misinterpretations in exome sequencing

8. Serum neurofilament light chain in distinct phenotypes of amyotrophic lateral sclerosis: A longitudinal, multicenter study

10. Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study

12. Uncovering genetic mimics in multiple sclerosis: A single-center clinical exome sequencing study.

13. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study

17. Multiomic ALS signatures highlight sex differences and molecular subclusters and identify the MAPK pathway as therapeutic target

18. Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy

21. Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis—a cross‐sectional multicenter study

24. Health-Related Quality of Life in Spinal Muscular Atrophy Patients and Their Caregivers—A Prospective, Cross-Sectional, Multi-Center Analysis

25. Spectrum and frequency of genetic variants in sporadic amyotrophic lateral sclerosis

27. Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy

30. Bi‐AllelicCOQ4Variants Cause Adult‐Onset Ataxia‐Spasticity Spectrum Disease

31. GFPT1-Associated Congenital Myasthenic Syndrome Mimicking a Glycogen Storage Disease – Diagnostic Pitfalls in Myopathology Solved by Next-Generation-Sequencing

32. Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment

33. Adult‐Onset Neurodegeneration in Nucleotide Excision Repair Disorders (NERD ND): Time to Move Beyond the Skin

35. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis

36. Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy

37. Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy

38. Detection of mobile elements insertions for routine clinical diagnostics in targeted sequencing data

39. Successful treatment with azacitidine in VEXAS syndrome with prominent myofasciitis

40. Transcript-Specific Loss-of-Function Variants in VPS16 Are Enriched in Patients With Dystonia

41. Sweet-Syndrom, Myofasziitis und myelodysplastisches Syndrom - eine seltene Koinzidenz mit einer noch selteneren Ursache

42. Bi-Allelic COQ4 Variants Cause Adult-Onset Ataxia-Spasticity Spectrum Disease.

43. sj-pdf-1-tan-10.1177_1756286421998902 – Supplemental material for Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy

44. Adult‐Onset Neurodegeneration in Nucleotide Excision Repair Disorders (NERDND): Time to Move Beyond the Skin.

45. Informal Caregiving in Amyotrophic Lateral Sclerosis (ALS): A High Caregiver Burden and Drastic Consequences on Caregivers’ Lives

46. Heterozygous UCHL1loss-of-function variants cause a neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy

47. A Nation-Wide, Multi-Center Study on the Quality of Life of ALS Patients in Germany

48. Defective phosphatidylethanolamine biosynthesis leads to a broad ataxia-spasticity spectrum

49. Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy

Catalog

Books, media, physical & digital resources